Abstract
Vascular complications of diabetes mellitus, including the evolution of the retinal damage known as diabetic retinopathy, have been recognized for centuries. Over the past decade, advances in technology such as retinal imaging and the development of new therapies have dramatically improved the evaluation, treatment, and visual outcomes of patients with diabetic retinopathy. Nonetheless, diabetic macular edema and proliferative diabetic retinopathy remain the leading causes of both moderate and severe vision loss in most developed countries. This article reviews the worldwide effect of diabetic retinopathy and recent changes in the evaluation and treatment of affected patients.
Original language | English (US) |
---|---|
Pages (from-to) | 1629-1637 |
Number of pages | 9 |
Journal | New England Journal of Medicine |
Volume | 382 |
Issue number | 17 |
DOIs | |
State | Published - Apr 23 2020 |
Funding
Dr. Jampol reports receiving consulting fees from Sanofi Pharmaceuticals; Mr. Glassman, receiving grant support, paid to his institution, from Genentech, Regeneron, and Allergan; and Dr. Sun, receiving grant support and provision of equipment from Optovue, provision of equipment from Boston Micro-machines and Adaptive Sensory Technologies, grant support and travel support from Kalvista, Novo Nordisk, and Boehringer Ingelheim, consulting fees and travel support from Merck and Novartis, and grant support, medical writing, and travel support from Roche. No other potential conflict of interest relevant to this article was reported.
ASJC Scopus subject areas
- General Medicine